Abstracts Archive - Page 987 of 2425 - ACR Meeting Abstracts

Abstract Number: 490 • 2019 ACR/ARP Annual Meeting
Validation of Risk Scores for Predicting Progression in Individuals “At Risk of Rheumatoid Arthritis”
Laurence Duquenne¹, Jacqueline Nam ², Kulveer Mankia ², Andrea Di Matteo ², Leticia Garcia-Montoya ² and Paul Emery ², ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, England, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom
Background/Purpose: Risk scores for progression have been described in 2015 in a cohort of 100 anti-cyclic citrullinated peptide (anti-CCP) positive individuals at risk of developing…
Abstract Number: 491 • 2019 ACR/ARP Annual Meeting
Diagnostic Performance of Anti-cyclic Citrullinated Peptide (CCP) 2 and CCP3.1 Assays in Early Rheumatoid Arthritis
Daniela Sieghart¹, Christian Konrad ², Sascha Swiniarski ², Helmuth Haslacher ³, Daniel Aletaha ⁴ and Günter Steiner ¹, ¹Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Vienna, Austria, Vienna, Austria, ²Thermo Fisher Scientific, Freiburg, Germany, Freiburg, Germany, ³Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁴Medical University of Vienna, Vienna, Austria
Background/Purpose: Anti-cyclic citrullinated peptide (CCP) antibodies are the most specific markers for rheumatoid arthritis (RA). Different generations of assays (CCP1-CCP3) have been developed which show…
Abstract Number: 492 • 2019 ACR/ARP Annual Meeting
‘It Felt Like I Was Walking on Rocks” Patients Share First Symptoms of RA
Pamela Sinicrope¹, Dana Symons ², Ahmad P. Tafti ¹, Christi Patten ¹, Martha Bock ¹, Jon Tilburt ¹, Cynthia Crowson ¹, Elena Myasoedova ¹, John Davis ¹ and Kelly O'Neill ³, ¹Mayo Clinic, Rochester, MN, ²Rheumatoid Patient Foundation, Inc., Rockford, MI, ³Rheumatoid Patient Foundation, Inc., Winter Springs, FL
Background/Purpose: Background: Although early diagnosis and treatment are pivotal for successful outcomes in rheumatoid arthritis (RA), a gap remains in our understanding of its earliest…
Abstract Number: 493 • 2019 ACR/ARP Annual Meeting
Diversity Analysis of Intestinal Flora in Patients with Rheumatoid Arthritis
Xu-fang Yin ¹, Sheng-xiao Zhang¹, Ming-xing Zhang ², Min-jing Chang ¹, Xiao-juan Mao ², Jia Wang ², Jia-qian Zhang ², Meng-ting Qiu ², Chong Gao ³ and Xiao-feng Li ², ¹The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China (People's Republic), ²The Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), ³Brigham and Women’s Hospital, Harvard Medical School, Boston
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammation of the synovial joints. The gut microbe with RA has been reported recently,…
Abstract Number: 494 • 2019 ACR/ARP Annual Meeting
Clinical and Biomarker Factor Associations with Symptoms and Future Development of RA: TIP-RA Collective
Kevin Deane¹, Sunil Nagpal ², V. Michael Holers ³, Gary Firestein ⁴, David Boyle ⁵, Jennifer Seifert ³, Jane Buckner ⁶, Eddie James ⁶, Laurakay Moss ⁷, Saman Barzideh ⁷, Sylvia Posso ⁶, William Robinson ⁸, Kristen Polinski ⁷, Roger Gilmore ⁷, Frédéric Baribaud ⁹, Navin Rao ² and George Vratsanos ¹⁰, ¹University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ²Janssen R&D, Spring House, PA, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁴University of California, San Diego, San Diego, ⁵University of California, San Diego, San Diego, CA, ⁶Benaroya Research Institute, Seattle, WA, ⁷University of Colorado Denver, Aurora, CO, ⁸Stanford University, Palo Alto, CA, ⁹Janssen Research & Development, LLC, Spring House, PA, ¹⁰JNJ, Raritan, NJ
Background/Purpose: The Targeting Immune Responses for Prevention of RA (TIP-RA) Collaborative prospectively studies individuals at high risk for developing RA because of serum ACPA positivity…
Abstract Number: 495 • 2019 ACR/ARP Annual Meeting
Pre-Rheumatoid Arthritis Diagnosis Prevalence of Commercial CCP Antibody Positivity Increases over Time with Strong Agreement Between Commercial Assays and Positivity Is Predicative of Developing Rheumatoid Arthritis Within 3 Years
Steven Taylor¹, Mark Parish ², LauraKay Moss ³, Marie Feser ⁴, Elizabeth Mewshaw ⁵, Jess Edison ⁵ and Kevin Deane ⁴, ¹University of Colorado - Denver, Denver, CO, ²University of Colorado Denver, Aurora, CO, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO USA, Aurora, CO, ⁴University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ⁵Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose: Rheumatoid arthritis (RA) related autoantibodies, in particular antibodies to citrullinated proteins (ACPA), predict likelihood of developing future RA. Indeed, clinical trials for RA prevention…
Abstract Number: 496 • 2019 ACR/ARP Annual Meeting
Assessment of Anti-Cyclic Citrullinated Protein and Connective Tissue Disease Screening Questionnaire in Healthy Adults from the Oklahoma Immune Cohort
McKayla Muse¹, Ly Tran ¹, Carla J. Guthridge ², Nancy Redinger ² and Judith James ³, ¹Oklahoma Medical Research Foundation, Oklahoma City, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Anti-CCP antibodies are present in the serum of healthy individuals who are at risk of developing RA and serve as an important tool for…
Abstract Number: 497 • 2019 ACR/ARP Annual Meeting
Women with Rheumatoid Arthritis Have Higher Lifetime Occupational and Non-occupational Exposure to Silica Dust Compared to French General Population
Johanna Sigaux¹, Catherine Cavalin ², Odile Macchi ², Salima Challal ³, Mylene Petit ⁴, Patrice Decker ⁵, Emma André ⁴, Paul-André rosental ², Marie-Christophe Boissier ⁶ and Luca Semerano ⁷, ¹INSERM UMR 1125, Université Paris 13, Bobigny, France, ²SILICOSIS project, ERC Advanced Grant, Centre for European Studies, Sciences Po, Paris, France, Paris, France, ³Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne Service de Rhumatologie, Bobigny, France, ⁴INSERM UMR 1125 Sorbonne Paris Cité, Université Paris 13, 93000 Bobigny, France, Paris, France, ⁵Inserm UMR 1125, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, ⁶Assistance Publique-Hôpitaux de Paris (AP-HP), Rheumatology Department, Avicenne Hospital, Bobigny, France, ⁷INSERM UMR 1125 , Université Paris 13, Bobigny, France
Background/Purpose: Occupational exposure to silica dust is a well-known risk factor for ACPA positive rheumatoid arthritis (RA). The role of non-occupational exposure has not been…
Abstract Number: 498 • 2019 ACR/ARP Annual Meeting
Should There Be Hierarchical Scoring Applied to Serologic Testing in the 2010 ACR/EULAR Classification Criteria?
Barbara Mascialino¹ and Teresa Tarrant ², ¹Thermo Fisher Scientific, Uppsala, Uppsala Lan, Sweden, ²Duke School of Medicine, Division of Rheumatology and Immunology, Durham, NC
Background/Purpose: The 2010 ACR/EULAR classification criteria for Rheumatoid Arthritis (RA) are based on a combination of clinical, laboratory, and imaging investigations. Positive serology contributes to…
Abstract Number: 499 • 2019 ACR/ARP Annual Meeting
The Generation of Anti-CCP Tests Affects Diagnostic Accuracy in Rheumatoid Arthiritis: A Systematic Literature Review and Meta-Analysis
Barbara Mascialino¹, Linda Mathsson-Alm ¹, Maryam Poorafshar ¹ and Teresa Tarrant ², ¹Thermo Fisher Scientific, Uppsala, Uppsala Lan, Sweden, ²Duke School of Medicine, Division of Rheumatology and Immunology, Durham, NC
Background/Purpose: The detection of antibodies to cyclic citrullinated peptides (anti-CCP) may occur long before the onset of rheumatoid arthritis (RA) symptoms.Several versions of CCP antigen…
Abstract Number: 500 • 2019 ACR/ARP Annual Meeting
The Dysregulation of NK Cells and Non-Conventional NK-T and γδ-T Cells in Individuals at Risk of Developing Rheumatoid Arthritis
Klára Prajzlerová¹, Olga Kryštůfková ², Petra Hánová ³, Hana Hulejová ³, Monika Gregová ¹, Nora Petrovská ¹, Herman Mann ⁴, Karel Pavelka ⁴, Jiří Vencovský ⁴, Ladislav Senolt ⁴ and Mária Filková ¹, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic
Background/Purpose: The positivity of antibodies against citrullinated proteins (ACPA) precedes the clinical manifestation and significantly increases the risk of rheumatoid arthritis (RA). EULAR characterised individuals…
Abstract Number: 501 • 2019 ACR/ARP Annual Meeting
EULAR Definition of “Arthralgia Suspicious for Progression to Rheumatoid Arthritis” in a Cohort of Patients Included in a Program for Rapid Diagnosis: Role of Ultrasound and Antibodies
Jessica Torres Chichande¹, Santiago Ruta ², Einer Sanchez Prado ³, Alvaro Ruta ¹, Sebastian Magri ¹, Facundo Salvatori ¹ and Rodrigo Garcia Salinas ¹, ¹Hospital Italiano de La Plata, La plata, Buenos Aires, Argentina, ²Rheumatology Department, Hospital San Martín de La Plata and Rheumatology Unit, Hospital Italiano de La Plata, Argentina., La Plata, Argentina, ³Hospital Italiano de La Plata, La Plata
Background/Purpose: To evaluate the performance of the EULAR definition of arthralgias suspicious for progression to rheumatoid arthritis (RA) in a group of patients admitted to…
Abstract Number: 502 • 2019 ACR/ARP Annual Meeting
Disease Activity Measures at Baseline and 3 Months as Predictors of Rapid Radiographic Progression in Methotrexate Naïve Patients with Early Rheumatoid Arthritis
Mohammad Movahedi ¹, Deborah Weber ¹, Pooneh Akhavan ² and Edward Keystone³, ¹Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ²Division of Rheumatology, Mount Sinai Hospital, Toronto, Canada, ³Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Progressive rheumatoid arthritis (RA) is responsible for disabilities in this patient population, characterized by radiographic joint damage. Achieving low disease activity (LDA) in RA…
Abstract Number: 503 • 2019 ACR/ARP Annual Meeting
A Pilot Phase 1, Randomized, Double-blind, Two-arm, Parallel Group, Single-dose Study to Evaluate the Safety and Pharmacokinetics of CT-P17 and Humira in Healthy Male Subjects
Edward Keystone¹, Daniel Furst ², Malcolm Boyce ³, Frans van den Berg ³, SangJoon Lee ⁴, SungHyun Kim ⁴, YunJu Bae ⁴, GoEun Yang ⁴, JuHeon Koo ⁴, EunJin Choi ⁴ and Jonathan Kay ⁵, ¹Mount Sinai Hospital, Toronto, Canada, ²University of California, Los Angeles, CA, ³Hammersmith Medicines Research, London, United Kingdom, ⁴Celltrion Inc., Incheon, Republic of Korea, ⁵UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA
Background/Purpose: CT-P17 is a recombinant humanized monoclonal antibody that was developed as a biosimilar to the reference product, adalimumab. This was a first in human…
Abstract Number: 504 • 2019 ACR/ARP Annual Meeting
A Subgroup Analysis of the Efficacy of Filgotinib in Demographic and Clinical Subgroups of Patients with Refractory Rheumatoid Arthritis
Kenneth Kalunian¹, Mark Genovese ², Jacques-Eric Gottenberg ³, Beatrix Bartok ⁴, Alena Pechonkina ⁴, Ying Guo ⁴, Chantal Tasset ⁵, John Sundy ⁴, Kurt de Vlam ⁶, David Walker ⁷ and Tsutomu Takeuchi ⁸, ¹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ²Stanford University, Stanford, CA, ³Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos NV, Mechelen, Belgium, ⁶Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, ⁷Northumbria Healthcare, Northumbria, United Kingdom, ⁸Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: RA patients who have failed biologic DMARDs represent an unmet medical need. We explored the impact of baseline demographics and clinical characteristics on filgotinib…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].